Highly rated in
Highly rated in
Check Dr. Peter I. Karachunski's experience treating your condition:
About Dr. Peter I. Karachunski

Peter Karachunski is a Neurologist and a Pediatrics expert in Minneapolis, Minnesota. Karachunski has been practicing medicine for over 35 years and is highly rated in 24 conditions, according to our data. His top areas of expertise are Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, and Limb-Girdle Muscular Dystrophy. He is licensed to treat patients in Minnesota. Karachunski is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 6 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Peter I. Karachunski it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Peter I. Karachunski accepts the following insurance:

  •  Ambetter
  •  Bright Health
  •  Medica
  •  HealthPartners

Call to see if your plan is accepted.
2512 S 7th St, Floor 3, Minneapolis, MN 55454
Other Locations
909 Fulton St. Se, Suite 2-201, Minneapolis, MN 55455
2450 Riverside Ave Se, Minneapolis, MN 55455
Background & Education
Graduate Institution
Other, 1987
Child & Adolescent Psychiatry in MN
Hospital Affiliations
M Health Fairview University Of Minnesota Medical Center - West Bank Hospital
Gillette Childrens Specialty Health
Allina Health Faribault Medical Center
Abbott Northwestern Hospital
Memorial Medical Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
View 4 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors